• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Chew on this: New oral feline flea preventive approved

January 3, 2020
dvm360.com staff

Credelio Cat from Elanco has been approved for monthly use to prevent and treat flea infestations in cats.

Last month, the FDA Center for Veterinary Medicine approved Credelio CAT (lotilaner—Elanco US), an oral product that kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) for one month in cats and kittens 8 weeks of age and older and weighing at least 2 lb.

The chewable tablets will be available by prescription only and must be given with food. Credelio Cat will be sold in two sizes: 12 mg lotilaner for cats weighing 2 to 4 lb, and 48 mg lotilaner for cats weighing 4.1 to 17 lb. Cats weighing over 17 lb can be a given the appropriate combination of tablets.

According to the product’s Freedom of Information Summary, the effectiveness of Credelio Cat was demonstrated in three laboratory studies and one field study enrolling a total of 40 laboratory cats and 228 client-owned cats. These studies showed that Credelio Cat is effective for the treatment and prevention of flea infestations for one month. The most common adverse reactions included weight loss, tachypnea, vomiting, diarrhea, anorexia and elevated blood urea nitrogen.

Credelio Cat was launched in Europe just over a year ago for the treatment and prevention of both flea and tick infestations in cats.

Advertisement

Lotilaner, the active ingredient in Credelio CAT, falls into the isoxazoline class of compounds that are the latest parasiticides for use in companion animals. (Others include afoxolaner, fluralaner and sarolaner.) These drugs kill fleas by targeting nervous system receptors. In 2018, the FDA warned veterinarians and pet owners to be aware of the potential for neurologic adverse events in dogs and cats treated with drugs in the isoxazoline class.

Elanco has not specified when Credelio Cat will be available in the United States. Keri McGrath Happe, Elanco’s head of North American communications, says, “While we’re excited at the potential Credelio Cat has to offer cat and kitten owners, we can’t speculate as to the exact launch timing as there are additional opportunities we are pursuing for the brand prior to commercial launch.”

Related Content:

Products
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched
dvm360® product report: One Health microsite, plus mushroom equine supplement and more
dvm360® product report: One Health microsite, plus mushroom equine supplement and more
dvm360® product report: ear dehumidifier, plus dental artificial intelligence and more
dvm360® product report: ear dehumidifier, plus dental artificial intelligence and more

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement